Base Editing Market Size 2025-2029
The base editing market size is forecast to increase by USD 358.8 million, at a CAGR of 15.4% between 2024 and 2029.
The global base editing market is driven by the profound unmet medical need for curative treatments for thousands of genetic disorders caused by single-point mutations. This technology offers the potential for a one-time, permanent therapeutic intervention through precise dna modification. A pivotal trend shaping this market is the strategic shift toward in vivo therapies, moving beyond the limitations of ex vivo cell processing. This approach, often using non-viral delivery systems like lipid nanoparticles, expands the therapeutic targeting scope to a vast array of diseases. This evolution in genome engineering requires advanced sample preparation and analysis.However, a primary challenge involves persistent concerns regarding off-target effects and the long-term safety of making permanent genomic alterations, a critical consideration for the genome editing market. The risk of unintended genomic alterations, including off-target mutations and bystander mutations, necessitates extensive preclinical safety assessment and long-term patient monitoring. This uncertainty places a heavy burden of proof on developers navigating complex regulatory pathways. These safety hurdles directly impact the development of gene correction therapies and underscore the need for rigorous validation at every stage, from discovery to clinical application, reflecting a model based enterprise approach to therapeutic development.
What will be the Size of the Base Editing Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The continuous evolution in the base editing market is centered on refining editor protein engineering and deaminase enzyme evolution. These efforts are geared toward enhancing on-target editing fidelity and minimizing unintended alterations, which are critical for the safe application of precise DNA modification techniques. The development of advanced platforms is a key focus within the broader genome editing market, as researchers work to improve the core components of the technology for therapeutic use. This dedication to iterative improvement ensures that the tools become progressively safer and more effective.The expanding application of base editing technologies from monogenic disease correction to therapeutic gene silencing for more common, complex disorders is reshaping the field's strategic landscape. This transition necessitates innovations in ensuring guide RNA specificity and developing robust in vivo delivery systems. The progress in this area is pivotal for the overall therapeutic pipeline expansion, demonstrating the technology's versatility beyond its initial applications in genome engineering and showing its potential in a model based enterprise framework.Progress in enabling technologies, particularly in AAV delivery optimization and lipid nanoparticle delivery, is fundamental to translating mRNA-based therapeutics from laboratory research to clinical reality. Overcoming challenges associated with cellular delivery mechanisms is crucial for the success of in vivo therapies. Effective and targeted delivery ensures that the editing machinery reaches the correct cells with high efficiency, which is a prerequisite for achieving therapeutic benefit and is reliant on robust sample preparation and analysis.
How is this Base Editing Industry segmented?
The base editing industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Type
- DNA base editing
- RNA base editing
- Application
- Drug discovery and development
- Agriculture
- Veterinary
- End-user
- Academic and research institutes
- Contract research organizations
- Pharmaceutical and biotechnology
- Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- The Netherlands
- Spain
- Russia
- Asia
- Rest of World (ROW)
By Type Insights
The dna base editing segment is estimated to witness significant growth during the forecast period.
DNA base editing stands as the foundational and predominant segment within the market. This technology facilitates precise and permanent alterations directly within a cell's genomic DNA. Its mechanism employs a catalytically impaired Cas enzyme, which serves as a programmable guide, fused to a deaminase enzyme. This molecular construct is directed to a specific genomic location, where it chemically converts one nucleotide base into another without inducing double-strand breaks. About 65% of known human pathogenic genetic variants are point mutations, representing a vast target area.
The primary advantage of this method is its permanency, offering the potential for a one-time, curative therapy for a wide range of monogenic diseases. This prospect is the main force driving research and investment. However, the irreversible nature of these edits necessitates exceptional on-target editing fidelity to prevent unintended genomic alterations. Consequently, a significant portion of innovation is concentrated on enhancing the specificity of editor proteins and improving cellular delivery mechanisms to ensure both safety and efficacy in therapeutic applications.
Request Free Sample
The DNA base editing segment was valued at USD 125.70 million in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 35.2% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
North America currently leads the global base editing market, a position established through substantial and sustained investment in research and development activities for gene correction therapies. The region, particularly the US, is the epicenter for a high volume of clinical trials and benefits from a clear and proactive regulatory framework that facilitates more predictable regulatory pathway navigation for developers. This environment encourages investment and solidifies the region's leadership in both scientific discovery and commercial translation, with the region accounting for over 35% of the market's incremental growth.
The dominance of North America is further reinforced by considerable government funding streams for biomedical research, which act as a catalyst for therapeutic pipeline expansion. This robust infrastructure supports a significant volume of preclinical safety assessment activities and the majority of ongoing global clinical trials for base editing therapeutics. This comprehensive ecosystem, combining financial backing, regulatory clarity, and a strong research base, firmly establishes the region's preeminent position and attracts top-tier global talent and capital investment.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global base editing market is expanding, driven by high-fidelity base editor development and dual-deaminase base editors for expanded targeting. These innovations are crucial for applications from allogeneic CAR-T cell engineering to the promising field of in vivo base editing for cardiovascular disease. Researchers are using sophisticated guide RNA design for targeted gene modification and exploring frontiers like mitochondrial DNA base editing techniques. CRISPR cytosine base editor screen applications accelerate discovery, while comparison with therapeutic gene silencing with CRISPR highlights base editing's precision. The availability of tools such as Pin-point base editing platform reagents is empowering the development of next-generation treatments, including gene-edited allogeneic CAR T-cell therapies, which are poised to revolutionize oncology.Navigating commercialization presents hurdles, including overcoming AAV-mediated gene delivery challenges and optimizing lipid nanoparticle formulation for mRNA alongside other non-viral delivery systems in gene therapy. Rigorous preclinical off-target analysis methodologies and reliable methods for detecting off-target edits are paramount for meeting stringent regulatory compliance for gene-edited therapies. Satisfying complex CMC requirements for advanced therapies is another critical step. Beyond human health, base editing technology for crop trait improvement is opening new revenue streams. As these technologies mature, the industry is debating innovative payment models for one-time curative treatments and conducting siRNA and ASO comparative analysis to position base editing effectively within the therapeutic landscape.
What are the key market drivers leading to the rise in the adoption of Base Editing Industry?
- The increasing prevalence of genetic disorders and substantial unmet medical needs for curative treatments serves as a primary and fundamental driver for the global base editing market.
A primary driver for the global base editing market is the significant burden of genetic diseases, for which current treatments are often limited to symptomatic management rather than a definitive cure. Base editing technology offers the potential for a one-time, permanent therapeutic intervention by directly correcting the underlying single-point mutations. This prospect of gene correction therapies creates a compelling value proposition for patients and a substantial commercial opportunity that propels therapeutic pipeline expansion. Thousands of human diseases are caused by single-point mutations, validating the platform and stimulating further research and investment across the field, especially in genetic disease modeling.Continuous technological innovation that enhances the precision, efficiency, and safety of base editing systems is a critical driver of market growth. Unlike first-generation gene editing, base editing operates through single-nucleotide base conversion without cleaving the DNA backbone, significantly reducing the risk of unintended genomic alterations. This superior safety profile is a major factor in its adoption for therapeutic development. Ongoing innovations, such as the creation of high-fidelity base editors and dual-function base editors, are expanding the therapeutic targeting scope and minimizing off-target mutations, thereby building confidence among researchers, regulators, and investors.
What are the market trends shaping the Base Editing Industry?
- A defining market trend is the strategic and technological shift from ex vivo methods toward in vivo therapeutic approaches, which are increasingly coupled with non-viral delivery systems.
A defining trend is the strategic shift from ex vivo to in vivo therapeutic approaches, increasingly paired with non-viral delivery systems. While ex vivo methods are logistically complex and limited to accessible cells, in vivo base editing allows for direct editing within the body, opening up treatment for a vast array of diseases affecting organs like the liver and central nervous system. Coinciding with this is a preference for lipid nanoparticle delivery, which offers advantages over viral vectors, including lower immunogenicity risk and the ability to carry larger mRNA-based therapeutics. This trend represents the next frontier of genome engineering, aiming for more accessible treatments for a broader spectrum of human diseases.Another significant trend is the expansion of base editing applications beyond rare monogenic diseases into more prevalent and complex conditions. While monogenic disease correction remains a core focus, the industry is now leveraging the precision of base editing for multifactorial diseases like cardiovascular disease through therapeutic gene silencing of risk-contributing genes. In oncology, it is a key enabling technology for allogeneic CAR-T cell engineering. This therapeutic scope expansion dramatically increases the addressable market for base editing technologies, moving them from niche applications to mainstream medicine. Globally, around 15 million people die before the age of 70 years every year due to chronic diseases, highlighting the potential impact.
What challenges does the Base Editing Industry face during its growth?
- A paramount challenge confronting the industry is the persistent concern regarding off-target effects and the unknown long-term safety consequences of making permanent alterations to the human genome.
A paramount challenge is the concern regarding off-target effects and the long-term consequences of permanent genomic alterations. Although designed for precision, the risk of unintended genomic alterations, such as off-target mutations or bystander mutations at the target site, is not eliminated. These events carry the theoretical risk of severe adverse effects, including the disruption of essential genes or oncogene activation. Proving long-term safety requires extensive preclinical safety assessment and lengthy patient monitoring, placing a heavy burden on drug developers. This high bar for safety, where the majority of the US population lives with at least one chronic condition, sets a rigorous precedent for all gene correction therapies.The clinical translation and commercialization of base editing therapies are significantly challenged by the immense technical complexity and high cost of manufacturing and delivery. Ex vivo therapies require a sophisticated, personalized, and logistically demanding manufacturing process that is difficult to scale. In vivo therapies face the critical challenge of safe and efficient delivery to target tissues, with both viral and non-viral delivery systems presenting distinct hurdles related to immunogenicity, payload capacity, and biodistribution. These manufacturing process validation and delivery bottlenecks slow clinical development and contribute directly to the high price of the final therapeutic products.
Exclusive Customer Landscape
The base editing market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the base editing market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, base editing market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Beam Therapeutics Inc. - The company provides a range of proprietary base editing technologies and platforms, such as the REPAIR and RESCUE systems, Target-AID, and the TaRGET platform, designed for the development of precision genetic medicines. These offerings encompass solutions for A-to-I and C-to-U editing, cytosine deaminase base editors, and hypercompact CRISPR-based systems optimized for in-vivo gene therapy applications. The technology is applied across various domains, including creating therapeutic products for serious genetic diseases, developing tools for plant and crop science, and providing analysis platforms for detecting genomic alterations in gene and cell therapies. These solutions are pivotal for both internal drug development pipelines and for enabling research and development activities across the broader life sciences industry.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Beam Therapeutics Inc.
- Bio Palette Co., Ltd.
- Cellectis
- Creative Biogene
- Danaher Corp.
- EdiGene Inc.
- ElevateBio
- Genkore
- GenScript Biotech Corp.
- Intellia Therapeutics Inc.
- KROMATID
- Maravai LifeSciences Holdings Inc.
- Merck KGaA
- Pairwise
- PerkinElmer U.S. LLC
- Qi Biodesign Technology
- ShapeTX
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Base Editing Market
In May 2024, Profluent, an AI-native biotechnology company, announced the creation of OpenCRISPR-1, the first open-source, AI-generated gene editor, demonstrating that AI can be used to design novel and functional gene editing systems from scratch.In February 2024, researchers from the Gladstone Institutes and the University of California, San Francisco, reported a novel strategy in nonhuman primates using a base editor fused to an epigenome editor to durably silence the PCSK9 gene, a key target for lowering cholesterol.In January 2024, Beam Therapeutics announced its strategic priorities, which included advancing its allogeneic CAR-T programs, such as BEAM-201 for T-cell malignancies, showcasing the application of base editing in creating next-generation cancer therapies.In January 2024, Vertex Pharmaceuticals began discussions with payers regarding the pricing of its newly approved gene therapy, Casgevy, which has a list price of $2.2 million, highlighting the reimbursement challenges facing high-cost curative therapies.
Research Analyst Overview
The evolution of the global base editing market is characterized by advancements beyond the traditional crispr-cas9 system, focusing on precise single-nucleotide base conversion. The fields of dna base editing and rna base editing are advancing to address single-point mutations central to many monogenic diseases. This involves sophisticated guide rna design and continuous deaminase enzyme evolution, utilizing variants like adenosine deaminase and cytosine deaminase. The objective remains the refinement of gene correction therapies through editor protein engineering to enhance on-target editing fidelity. The development of specialized tools, including the epigenome editor, dual-function base editors, and mitochondrial base editors, is broadening the therapeutic targeting scope for applications ranging from genetic disease modeling to direct therapeutic interventions, fundamentally shifting how genetic disorders are approached.Translating these technologies into clinical applications involves navigating complex cellular delivery mechanisms for both ex vivo therapies, such as allogeneic CAR-T cell modification, and direct in vivo therapies. The use of lipid nanoparticles and other non-viral delivery methods, alongside AAV delivery optimization for mrna-based therapeutics, is pivotal. A critical focus remains on ensuring safety through rigorous preclinical safety assessment to mitigate off-target effects, bystander mutations, and other unintended genomic alterations. This meticulous approach is essential for therapeutic target validation, including pcsk9 gene inactivation, and for successful regulatory pathway navigation. As the field matures, processes like ex vivo cell processing and manufacturing process validation become standardized to support therapeutic pipeline expansion, with current models indicating nearly 25% of advanced therapy pipelines now integrate base editing techniques.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Base Editing Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
286
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 15.4%
|
|
Market growth 2024-2029
|
USD 358.8 million
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
13.4%
|
|
Key countries
|
US, Canada, Mexico, Germany, UK, France, Italy, The Netherlands, Spain, Russia, China, Japan, India, South Korea, Indonesia, Thailand, Singapore, Australia, UAE, Brazil, South Africa, Saudi Arabia, Turkey
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Base Editing Market Research and Growth Report?
- CAGR of the Base Editing industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the base editing market growth of industry companies
We can help! Our analysts can customize this base editing market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Base Editing Market 2019 - 2023
- Historic Market Size - Data Table on Global Base Editing Market 2019 - 2023 ($ billion)
- 5.2 Type segment analysis 2019 - 2023
- Historic Market Size - Type Segment 2019 - 2023 ($ billion)
- 5.3 Application segment analysis 2019 - 2023
- Historic Market Size - Application Segment 2019 - 2023 ($ billion)
- 5.4 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
- 6 Qualitative Analysis
- 6.1 Impact of AI in the global base editing market
7 Five Forces Analysis
- 7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Type
- 8 Market Segmentation by Type
- 8.1 Market segments
- Chart on Type - Market share 2024-2029 (%)
- Data Table on Type - Market share 2024-2029 (%)
- 8.2 Comparison by Type
- Chart on Comparison by Type
- Data Table on Comparison by Type
- 8.3 DNA base editing - Market size and forecast 2024-2029
- Chart on DNA base editing - Market size and forecast 2024-2029 ($ billion)
- Data Table on DNA base editing - Market size and forecast 2024-2029 ($ billion)
- Chart on DNA base editing - Year-over-year growth 2024-2029 (%)
- Data Table on DNA base editing - Year-over-year growth 2024-2029 (%)
- 8.4 RNA base editing - Market size and forecast 2024-2029
- Chart on RNA base editing - Market size and forecast 2024-2029 ($ billion)
- Data Table on RNA base editing - Market size and forecast 2024-2029 ($ billion)
- Chart on RNA base editing - Year-over-year growth 2024-2029 (%)
- Data Table on RNA base editing - Year-over-year growth 2024-2029 (%)
- 8.5 Market opportunity by Type
- Market opportunity by Type ($ billion)
- Data Table on Market opportunity by Type ($ billion)
9 Market Segmentation by Application
- 9 Market Segmentation by Application
- 9.1 Market segments
- Chart on Application - Market share 2024-2029 (%)
- Data Table on Application - Market share 2024-2029 (%)
- 9.2 Comparison by Application
- Chart on Comparison by Application
- Data Table on Comparison by Application
- 9.3 Drug discovery and development - Market size and forecast 2024-2029
- Chart on Drug discovery and development - Market size and forecast 2024-2029 ($ billion)
- Data Table on Drug discovery and development - Market size and forecast 2024-2029 ($ billion)
- Chart on Drug discovery and development - Year-over-year growth 2024-2029 (%)
- Data Table on Drug discovery and development - Year-over-year growth 2024-2029 (%)
- 9.4 Agriculture - Market size and forecast 2024-2029
- Chart on Agriculture - Market size and forecast 2024-2029 ($ billion)
- Data Table on Agriculture - Market size and forecast 2024-2029 ($ billion)
- Chart on Agriculture - Year-over-year growth 2024-2029 (%)
- Data Table on Agriculture - Year-over-year growth 2024-2029 (%)
- 9.5 Veterinary - Market size and forecast 2024-2029
- Chart on Veterinary - Market size and forecast 2024-2029 ($ billion)
- Data Table on Veterinary - Market size and forecast 2024-2029 ($ billion)
- Chart on Veterinary - Year-over-year growth 2024-2029 (%)
- Data Table on Veterinary - Year-over-year growth 2024-2029 (%)
- 9.6 Market opportunity by Application
- Market opportunity by Application ($ billion)
- Data Table on Market opportunity by Application ($ billion)
10 Market Segmentation by End-user
- 10 Market Segmentation by End-user
- 10.1 Market segments
- Chart on End-user - Market share 2024-2029 (%)
- Data Table on End-user - Market share 2024-2029 (%)
- 10.2 Comparison by End-user
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- 10.3 Academic and research institutes - Market size and forecast 2024-2029
- Chart on Academic and research institutes - Market size and forecast 2024-2029 ($ billion)
- Data Table on Academic and research institutes - Market size and forecast 2024-2029 ($ billion)
- Chart on Academic and research institutes - Year-over-year growth 2024-2029 (%)
- Data Table on Academic and research institutes - Year-over-year growth 2024-2029 (%)
- 10.4 Contract research organizations - Market size and forecast 2024-2029
- Chart on Contract research organizations - Market size and forecast 2024-2029 ($ billion)
- Data Table on Contract research organizations - Market size and forecast 2024-2029 ($ billion)
- Chart on Contract research organizations - Year-over-year growth 2024-2029 (%)
- Data Table on Contract research organizations - Year-over-year growth 2024-2029 (%)
- 10.5 Pharmaceutical and biotechnology - Market size and forecast 2024-2029
- Chart on Pharmaceutical and biotechnology - Market size and forecast 2024-2029 ($ billion)
- Data Table on Pharmaceutical and biotechnology - Market size and forecast 2024-2029 ($ billion)
- Chart on Pharmaceutical and biotechnology - Year-over-year growth 2024-2029 (%)
- Data Table on Pharmaceutical and biotechnology - Year-over-year growth 2024-2029 (%)
- 10.6 Market opportunity by End-user
- Market opportunity by End-user ($ billion)
- Data Table on Market opportunity by End-user ($ billion)
11 Customer Landscape
- 11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 12.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 12.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.4.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.4.5 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 12.4.6 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 12.4.7 Russia - Market size and forecast 2024-2029
- Chart on Russia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Russia - Market size and forecast 2024-2029 ($ billion)
- Chart on Russia - Year-over-year growth 2024-2029 (%)
- Data Table on Russia - Year-over-year growth 2024-2029 (%)
- 12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 12.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.5.2 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.5.3 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 12.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 12.5.5 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 12.5.6 Thailand - Market size and forecast 2024-2029
- Chart on Thailand - Market size and forecast 2024-2029 ($ billion)
- Data Table on Thailand - Market size and forecast 2024-2029 ($ billion)
- Chart on Thailand - Year-over-year growth 2024-2029 (%)
- Data Table on Thailand - Year-over-year growth 2024-2029 (%)
- 12.5.7 Singapore - Market size and forecast 2024-2029
- Chart on Singapore - Market size and forecast 2024-2029 ($ billion)
- Data Table on Singapore - Market size and forecast 2024-2029 ($ billion)
- Chart on Singapore - Year-over-year growth 2024-2029 (%)
- Data Table on Singapore - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 12.6.1 Australia - Market size and forecast 2024-2029
- Chart on Australia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Australia - Market size and forecast 2024-2029 ($ billion)
- Chart on Australia - Year-over-year growth 2024-2029 (%)
- Data Table on Australia - Year-over-year growth 2024-2029 (%)
- 12.6.2 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 12.6.3 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 12.6.4 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 12.6.5 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 12.6.6 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
13 Drivers, Challenges, and Opportunity
- 13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Increasing prevalence of genetic disorders and unmet medical needs
- Technological advancements enhancing precision and safety
- Rising investment and strategic collaborations
- 13.2 Market challenges
- Off-target effects and long-term safety concerns
- Complexities and high cost of manufacturing and delivery
- Stringent regulatory hurdles and uncertain reimbursement landscape
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Shift toward in vivo therapies and non-viral delivery systems
- Expansion of therapeutic scope beyond monogenic diseases
- Integration of artificial intelligence and machine learning in editor design
14 Competitive Landscape
- 14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15 Competitive Analysis
- 15.1 Companies profiled
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Beam Therapeutics Inc.
- Beam Therapeutics Inc. - Overview
- Beam Therapeutics Inc. - Product / Service
- Beam Therapeutics Inc. - Key offerings
- SWOT
- 15.5 Bio Palette Co., Ltd.
- Bio Palette Co., Ltd. - Overview
- Bio Palette Co., Ltd. - Product / Service
- Bio Palette Co., Ltd. - Key offerings
- SWOT
- 15.6 Cellectis
- Cellectis - Overview
- Cellectis - Product / Service
- Cellectis - Key offerings
- SWOT
- 15.7 Creative Biogene
- Creative Biogene - Overview
- Creative Biogene - Product / Service
- Creative Biogene - Key offerings
- SWOT
- 15.8 Danaher Corp.
- Danaher Corp. - Overview
- Danaher Corp. - Business segments
- Danaher Corp. - Key news
- Danaher Corp. - Key offerings
- Danaher Corp. - Segment focus
- SWOT
- 15.9 EdiGene Inc.
- EdiGene Inc. - Overview
- EdiGene Inc. - Product / Service
- EdiGene Inc. - Key offerings
- SWOT
- 15.10 ElevateBio
- ElevateBio - Overview
- ElevateBio - Product / Service
- ElevateBio - Key offerings
- SWOT
- 15.11 Genkore
- Genkore - Overview
- Genkore - Product / Service
- Genkore - Key offerings
- SWOT
- 15.12 GenScript Biotech Corp.
- GenScript Biotech Corp. - Overview
- GenScript Biotech Corp. - Business segments
- GenScript Biotech Corp. - Key news
- GenScript Biotech Corp. - Key offerings
- GenScript Biotech Corp. - Segment focus
- SWOT
- 15.13 Intellia Therapeutics Inc.
- Intellia Therapeutics Inc. - Overview
- Intellia Therapeutics Inc. - Product / Service
- Intellia Therapeutics Inc. - Key offerings
- SWOT
- 15.14 KROMATID
- KROMATID - Overview
- KROMATID - Product / Service
- KROMATID - Key offerings
- SWOT
- 15.15 Merck KGaA
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key news
- Merck KGaA - Key offerings
- Merck KGaA - Segment focus
- SWOT
- 15.16 Pairwise
- Pairwise - Overview
- Pairwise - Product / Service
- Pairwise - Key offerings
- SWOT
- 15.17 PerkinElmer U.S. LLC
- PerkinElmer U.S. LLC - Overview
- PerkinElmer U.S. LLC - Business segments
- PerkinElmer U.S. LLC - Key offerings
- PerkinElmer U.S. LLC - Segment focus
- SWOT
- 15.18 ShapeTX
- ShapeTX - Overview
- ShapeTX - Product / Service
- ShapeTX - Key offerings
- SWOT
16 Appendix
- 16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.5 Data procurement
- 16.6 Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
